Home・Список акций・Vir Biotechnology Inc

Vir Biotechnology Inc

Закрыт

СекторЗдравоохранение

9.18 3.15

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

8.86

Макс.

9.26

Ключевые показатели
By Trading Economics
Доход	-83M -126M
Продажи	-64M -29K
Прибыль на акцию	-0.85
Рентабельность продаж	433,431.034
Сотрудники	367
EBITDA	-83M -123M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+140.79% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-176M 1.5B
Предыдущая цена открытия	6.03
Предыдущая цена закрытия	9.18

Новостные настроения

By Acuity

67%

33%

291 / 340 Рейтинг в Healthcare

Vir Biotechnology Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 19:46 UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

30 июл. 2026 г., 19:58 UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

29 июл. 2026 г., 19:27 UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

28 июл. 2026 г., 15:46 UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

27 июл. 2026 г., 20:07 UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

25 июл. 2026 г., 00:01 UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

24 июл. 2026 г., 23:31 UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

21 июл. 2026 г., 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

20 июл. 2026 г., 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Сравнение c конкурентами

Изменение цены

Vir Biotechnology Inc Прогноз

Целевая цена

By TipRanks

140.79% рост

Прогноз на 12 месяцев

Средняя 21.43 USD 140.79%

Максимум 30 USD

Минимум 16 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для Vir Biotechnology Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

9 ratings

Покупка

Удержание

Продажа

Основано на мнении 9 аналитиков, присваивавших рейтинги акциям Vir Biotechnology Inc – Данные за последние 3 месяца.

Настроения

By Acuity

291 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.